#Australia #LabConnect #Clinical Trials #Port Melbourne #ACL

LabConnect and ACL Join Forces in Asia Pacific

In a landmark development for the clinical trials landscape, LabConnect has entered a strategic partnership with Australian Clinical Labs' (ACL) Specialised Trials. This collaboration aims to enhance the support for clinical trials within Australia and the broader Asia-Pacific region. The exclusive multi-year agreement is designed to leverage the unique strengths of both organizations to cater to the burgeoning demand for clinical trial services from pharmaceutical, biotechnology, and clinical research entities.

ACL Specialised Trials stands as one of Australia's premier clinical trials laboratories, adept in managing diverse biotech and pharmaceutical trials ranging from Phase 1 through Phase 4 studies. With a well-established network of laboratories positioned throughout Australia, ACL is equipped with vast experience delivering comprehensive pathology solutions and a broad spectrum of central laboratory services for clinical trials.

Melinda McGrath, Executive CEO of ACL, emphasized the significance of this partnership, stating, “This long-term partnership will help global clients access Australian patients and bring key international trials to this part of the world—ultimately resulting in advancements in medical breakthroughs that can save lives and enhance patient outcomes.” She highlighted the opportunity it presents for ACL to reinforce its role in an expanding $8 billion market while showcasing the expertise of its dedicated team on an international platform.

LabConnect is recognized as a leading central laboratory solutions provider, known for its agility and technology-driven approach. By aligning with ACL, LabConnect will enhance its service offerings in the region, including key functions such as in-country lab kit assembly, biospecimen management, data management, and logistics support. Catherine Osborne, the General Manager for APAC at LabConnect, oversees the company’s expanding footprint and operations throughout the region.

As the primary laboratory services partner for LabConnect in Australia and the Asia Pacific, ACL Specialised Trials will utilize their Port Melbourne facility as the operational center. Wes Wheeler, CEO of LabConnect, noted, “With the increasing interest from our clients in Asian Pacific sites for clinical developments, our partnership with ACL Specialised Trials gives us a robust platform to provide a comprehensive range of industry-leading central laboratory services throughout the region.”

About ACL Specialised Trials

ACL Specialised Trials, a subsidiary of Australian Clinical Labs, embodies a commitment to enhancing patient lives through exceptional medical practices, advanced technology, and a skilled workforce. Their specialized focus on Phase I-IV clinical trials ensures a meticulous and quality-driven service offering to their clients.

The state-of-the-art facility, coupled with extensive experience in commercial and clinical trials, enables a smooth transition from initial engagement to successful trial completion. Additional services include customized pathology approaches and a robust infrastructure designed to facilitate groundbreaking clinical research.

About LabConnect

LabConnect prides itself on being the most agile solutions partner for central laboratories globally, providing tailored, scalable support for clinical trials regardless of size or complexity. With a legacy of over two decades and involvement in more than 1,900 clinical studies across 93 countries, LabConnect has established itself as a trusted ally for biotechnology and pharmaceutical firms.

The company has strategically allied with leading laboratories worldwide, enabling them to offer cutting-edge innovation and automation. Their extensive suite of services includes customized lab kits, integrated logistics, standardized sample processing across the globe, and access to an expansive testing menu comprising over 10,200 validated assays. In addition, LabConnect provides scientific expertise to support every phase of clinical research, from pre-clinical studies to data management, ensuring a cohesive and submission-ready dataset.

Conclusion

The strategic partnership between LabConnect and ACL Specialised Trials is poised to reshape the clinical trial landscape in Australia and the Asia Pacific region. By combining their strengths, both organizations aim to streamline the challenge of conducting clinical trials—ultimately providing better access to new therapies for patients in need. This collaboration underscores a commitment to advancing medical research and improving outcomes for patients across the region.